UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
July 26, 2016
NEOGENOMICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
Nevada |
|
001-35756 |
|
74-2897368 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
|
12701 Commonwealth Drive, Suite 9, Fort Myers, Florida |
|
33913 |
(Address of principal executive offices) |
|
(Zip Code) |
(239) 768-0600
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
||
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
|
Item 2.02. |
Results of Operations and Financial Condition. |
On July 26, 2016, NeoGenomics, Inc. (the “Company”) issued a press release reporting its results for its second fiscal quarter of 2016. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
|
|
|
|
Item 9.01. |
Financial Statements and Exhibits. |
|
|
|
|
(a) |
Not applicable |
|
|
|
|
(b) |
Not applicable |
|
|
|
|
(c) |
Not applicable |
|
|
|
|
(d) |
Exhibits. |
|
|
|
|
99.1 |
Press Release of NeoGenomics, Inc. dated July 26, 2016. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
NEOGENOMICS, INC. |
|
|
|
By: |
|
/s/ George Cardoza |
|
|
George Cardoza |
|
|
Chief Financial Officer |
Date: July 26, 2016
3
Exhibit Index
|
|
|
|
|
|
Exhibit |
|
Description |
|
|
|
99.1 |
|
Press Release of NeoGenomics, Inc. dated July 26, 2016. |
4
EXHIBIT 99.1
NEOGENOMICS, INC.
PRESS RELEASE
FOR IMMEDIATE RELEASE
NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016
Integration of Clarient acquisition on track and progressing well.
Ft. Myers, Florida – July 26, 2016 - NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the second quarter of 2016.
Second Quarter 2016 Highlights:
|
· |
159% increase in consolidated revenue to record $63.1 million |
|
· |
158% increase in clinical genetic testing volume(1) |
|
· |
Net income of $413,000 versus net loss of $176,000 in Q2 2015 |
|
· |
281% increase in Adjusted EBITDA(2) to $9.2 million |
|
· |
Diluted EPS of ($0.07) per share and Adjusted Diluted EPS(2) of $0.04 per share |
Consolidated Revenue for the second quarter was $63.1 million, an increase of 159% over the same period last year. Clinical genetic test volume(1) grew 158% driven by the inclusion of Clarient’s results as well as a 32% year over year increase in base(3) NeoGenomics genetic test volume. Average revenue-per-test for clinical genetic tests decreased by 5% year over year to $385, primarily due to the inclusion of Clarient’s lower average reimbursement rate per test in the combined test mix.
Consolidated gross margin for the quarter was 45.3% as compared to 44.4% in last year’s second quarter. Gross margin improved due to a 4.4% reduction in average cost-of-goods-sold per clinical genetic test (“Cost per Test”) compared to the second quarter of 2015.
Consolidated selling, general and administrative expenses increased by $15.6 million, or 145%, from Quarter 2 2015, primarily as a result of the Clarient acquisition. Non-cash amortization of intangibles related to the Clarient acquisition and non-cash stock-based compensation expenses accounted for $2.5 million of this increase.
Interest expense for the quarter increased by $1.3 million from the second quarter of 2015 as a result of the bank debt incurred to finance the Clarient acquisition. Cash provided by operating activities was $5.0 million during the quarter.
Net income before allocation of non-cash preferred stock charges in Quarter 2 was $413,000, versus a net loss of ($176,000) in last year’s second quarter.
Non-cash “deemed preferred dividends” and non-cash amortization of the “beneficial conversion feature” related to preferred stock held by GE reduced net income attributable to common stockholders by $5.6 million, which resulted in net loss attributable to common stockholders of ($5.2 million) in Quarter 2 2016. Earnings per share attributable to common stockholders was ($0.07) in Quarter 2, versus ($0.00) per share in last year’s second quarter.
Adjusted EBITDA(2) was $9.2 million in the second quarter, an increase of 281% over the prior year. Adjusted Net Income(2) was $3.7 million, a 577% increase over the second quarter of 2015. Adjusted Diluted EPS(2) was $0.04 per share, versus $0.01 per share in Quarter 2 2015.
Douglas M. VanOort, the Company’s Chairman and CEO, commented, “We are very pleased with our second quarter performance. Market share gains continue to drive excellent performance in the base NeoGenomics business, and Clarient test volumes have stabilized nicely. Overall, we are pleased that our revenue growth has been so strong even as we are in the midst of significant integration activities.”
“In addition, our Bio Pharma business grew by 30% on a pro forma basis compared with Quarter 2 last year as we work on innovative projects with many of the world’s leading pharmaceutical firms. The combined capabilities of Clarient and NeoGenomics are making us a more attractive partner for BioPharma clients and their oncology-focused clinical trials. We are excited about the long-term prospects for this business, which now represents over 10% of our total revenue.”
Mr. VanOort continued, “Our teams are executing integration plans in a disciplined manner, and we are making good progress with the integration of Clarient. Although we have not yet implemented significant efficiency-related initiatives, we were able to grow Adjusted EBITDA by 281% and increase Adjusted EBITDA margin to 14.5% of revenue. We expect to realize additional cost synergies later in the year and especially in 2017 as a result of advances in our laboratory information system, adoption of best practices, consolidation of testing facilities and other integration activities currently being executed.”
Mr. VanOort concluded, “The acquisition of Clarient is clearly providing our company with many more opportunities. Clients are responding well as client retention remains strong, and the pipeline of new potential clients continues to be robust. Our ability to provide the best service offerings from each of Clarient and NeoGenomics to our combined client base should provide excellent growth potential as we complete our integration. We believe this, combined with our continual investments in new products and services, will allow us to continue our strong growth.”
Full-Year 2016 Financial Outlook:
NeoGenomics also today reiterated the guidance for fiscal year 2016 that was released with its Quarter 1, 2016 Earnings Release on April 27, 2016. The Company reserves the right to adjust this guidance at any time based on the ongoing execution of its business plan. Current and prospective investors are encouraged to perform their own due diligence before buying or selling any of the Company’s securities, and are reminded that the foregoing estimates should not be construed as a guarantee of future performance.
_____________________
(1) |
Clinical genetic tests exclude tests performed for BioPharma customers and tests performed by PathLogic. |
2
(3) |
To facilitate year over year comparisons, base NeoGenomics figures exclude the impacts from the consolidation of the PathLogic and Clarient acquisitions. |
Conference Call
The Company has scheduled a web-cast and conference call to discuss their Q2 2016 results on Tuesday, July 26, 2016 at 11:00 AM EDT. Interested investors should dial (877) 407-8035 (domestic) and (201) 689-8035 (international) at least five minutes prior to the call. A replay of the conference call will be available until 11:59 PM on August 9, 2016 and can be accessed by dialing (877) 481-4010 (domestic) and (919) 882-2331 (international). The playback conference ID Number is 10043. The web-cast may be accessed under the Investor Relations section of our website at http://neogenomics.com/ or http://investorcalendar.com/IC/CEPage.asp?ID=175124. An archive of the web-cast will be available until 11:59 PM on October 26, 2016.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for Physicians to help them diagnose and treat cancer. The Company’s BioPharma division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CLIA certified laboratories in Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Tampa and Fort Myers, Florida; Houston, Texas and Nashville, Tennessee. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States. For additional information about NeoGenomics, visit http://neogenomics.com/.
Forward Looking Statements
Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including the information set forth in the “Full-Year 2016 Financial Outlook”. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward looking statements as the result of the Company’s ability to continue gaining new customers, offer new types of tests, integrate its acquisition of the Clarient business, and otherwise implement its business plan, as well as additional factors discussed under the heading “Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2016 as amended on April 18, 2016. As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. In addition, it is the Company’s practice to make information about the Company available by posting copies of its Company Overview Presentation from time to time on the Investor Relations section of its website at http://ir.neogenomics.com/.
Forward-looking statements represent the Company’s estimates only as of the date such statements are made (unless another date is indicated) and should not be relied upon as representing the
3
Company’s estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its estimates change.
For further information, please contact:
NeoGenomics, Inc. Hawk Associates, Inc.
Steven C. JonesMs. Julie Marshall
Director of Investor Relations (305) 451-1888
(239) 325-2001 neogenomics@hawkassociates.com
sjones@neogenomics.com
4
NeoGenomics, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited, in thousands)
ASSETS |
|
June 30, 2016 |
|
|
|
|
December 31, 2015 |
|
|||||
Cash and cash equivalents |
|
$ |
21,786 |
|
|
|
|
$ |
23,420 |
|
|||
Accounts receivable (net of allowance for doubtful accounts of $9,197 and $4,759, respectively) |
|
|
53,513 |
|
|
|
|
|
48,943 |
|
|||
Inventory |
|
|
5,545 |
|
|
|
|
|
5,108 |
|
|||
Other current assets |
|
|
6,665 |
|
|
|
|
|
4,889 |
|
|||
Total current assets |
|
|
87,509 |
|
|
|
|
|
82,360 |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|||
Property and equipment (net of accumulated depreciation of $33,858 and $26,534, respectively) |
|
|
33,575 |
|
|
|
|
|
34,577 |
|
|||
Intangible assets, net |
|
|
84,164 |
|
|
|
|
|
87,800 |
|
|||
Goodwill |
|
|
146,179 |
|
|
|
|
|
146,421 |
|
|||
Other assets |
|
|
129 |
|
|
|
|
|
129 |
|
|||
TOTAL ASSETS |
|
$ |
351,556 |
|
|
|
|
$ |
351,287 |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|||
LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
|
|
|||
Accounts payable and other current liabilities |
|
$ |
29,616 |
|
|
|
|
$ |
26,055 |
|
|||
Short term portion of capital leases and senior debt |
|
|
5,337 |
|
|
|
|
|
14,003 |
|
|||
Total Current liabilities |
|
|
34,953 |
|
|
|
|
|
40,058 |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|||
Long-term Liabilities: |
|
|
|
|
|
|
|
|
|
|
|||
Long term portion of capital leases and senior debt |
|
|
56,986 |
|
|
|
|
|
57,376 |
|
|||
Deferred income tax liability, net |
|
|
16,249 |
|
|
|
|
|
15,741 |
|
|||
Total long-term liabilities |
|
|
73,235 |
|
|
|
|
|
73,117 |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|||
TOTAL LIABILITIES |
|
|
108,188 |
|
|
|
|
|
113,175 |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|||
Series A Redeemable Convertible Preferred Stock |
|
|
39,735 |
|
|
|
|
|
28,602 |
|
|||
Total Stockholders' equity |
|
|
203,633 |
|
|
|
|
|
209,510 |
|
|||
TOTAL LIABILITIES, SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY |
|
$ |
351,556 |
|
|
|
|
$ |
351,287 |
|
5
NeoGenomics, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
|
|
For the Three Months Ended June 30, |
|
|
For the Six Months Ended June 30, |
|
||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
Net Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical testing |
|
$ |
56,316 |
|
|
$ |
24,055 |
|
|
$ |
110,936 |
|
|
$ |
46,894 |
|
BioPharma & research |
|
|
6,813 |
|
|
|
315 |
|
|
|
11,896 |
|
|
|
502 |
|
Total Revenue |
|
|
63,129 |
|
|
|
24,370 |
|
|
|
122,832 |
|
|
|
47,396 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue |
|
|
34,524 |
|
|
|
13,557 |
|
|
|
67,055 |
|
|
|
27,040 |
|
Gross Profit |
|
|
28,605 |
|
|
|
10,813 |
|
|
|
55,777 |
|
|
|
20,356 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative |
|
|
18,779 |
|
|
|
7,075 |
|
|
|
36,785 |
|
|
|
13,598 |
|
Research and development |
|
|
1,306 |
|
|
|
803 |
|
|
|
2,752 |
|
|
|
1,471 |
|
Sales and marketing |
|
|
6,327 |
|
|
|
2,907 |
|
|
|
12,127 |
|
|
|
5,821 |
|
Total operating expenses |
|
|
26,412 |
|
|
|
10,785 |
|
|
|
51,664 |
|
|
|
20,890 |
|
Income (Loss) From Operations |
|
|
2,193 |
|
|
|
28 |
|
|
|
4,113 |
|
|
|
(534 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
1,448 |
|
|
|
189 |
|
|
|
3,040 |
|
|
|
384 |
|
Income (loss) before taxes |
|
|
745 |
|
|
|
(161 |
) |
|
|
1,073 |
|
|
|
(918 |
) |
Income tax expense |
|
|
332 |
|
|
|
15 |
|
|
|
505 |
|
|
|
19 |
|
Net Income (Loss) |
|
|
413 |
|
|
|
(176 |
) |
|
|
568 |
|
|
|
(937 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deemed dividends on preferred stock |
|
|
1,840 |
|
|
|
— |
|
|
|
3,680 |
|
|
|
— |
|
Amortization of preferred stock beneficial conversion feature |
|
|
3,727 |
|
|
|
— |
|
|
|
7,453 |
|
|
|
— |
|
Net (Loss) Attributable to Common Stockholders |
|
$ |
(5,154) |
|
|
$ |
(176 |
) |
|
$ |
(10,565) |
|
|
$ |
(937 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per Common Share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
(0.07) |
|
|
$ |
(0.00 |
) |
|
$ |
(0.14) |
|
|
$ |
(0.02 |
) |
Diluted |
|
$ |
(0.07) |
|
|
$ |
(0.00 |
) |
|
$ |
(0.14) |
|
|
$ |
(0.02 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Shares Used in Computation of Earnings per Common Share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
77,448 |
|
|
|
60,425 |
|
|
|
76,758 |
|
|
|
60,352 |
|
Diluted |
|
|
77,448 |
|
|
|
60,425 |
|
|
|
76,758 |
|
|
|
60,352 |
|
6
NeoGenomics, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, in thousands)
|
|
For the Six Months Ended June 30, |
|
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES |
|
2016 |
|
|
2015 |
|
||||
Net income (loss) |
|
$ |
568 |
|
|
$ |
(937 |
) |
||
Adjs. to reconcile net income (loss) to net cash provided by operating activities: |
|
|
|
|
|
|||||
Depreciation |
|
|
7,329 |
|
|
|
3,249 |
|
||
Amortization of debt issue costs |
|
|
358 |
|
|
|
- |
|
||
Amortization of intangible assets |
|
|
3,636 |
|
|
|
190 |
|
||
Non-cash warrant and stock based compensation |
|
|
2,337 |
|
|
|
1,020 |
|
||
Provision for bad debts |
|
|
5,434 |
|
|
|
1,303 |
|
||
Changes in assets and liabilities, net |
|
|
(7,567 |
) |
|
|
(2,928 |
) |
||
NET CASH PROVIDED BY OPERATING ACTIVITIES |
|
|
12,095 |
|
|
|
1,897 |
|
||
|
|
|
|
|
|
|
|
|
||
CASH FLOWS FROM INVESTING ACTIVITIES |
|
|
|
|
|
|
|
|
||
Purchases of property and equipment |
|
|
(3,425 |
) |
|
|
(1,180 |
) |
||
NET CASH USED IN INVESTING ACTIVITIES |
|
|
(3,425 |
) |
|
|
(1,180 |
) |
||
|
|
|
|
|
|
|
|
|
||
CASH FLOWS FROM FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
||
Repayments to revolving credit facility, net |
|
|
(10,044 |
) |
|
|
- |
|
||
Repayment of capital lease obligations, loans |
|
|
(2,611 |
) |
|
|
(1,833 |
) |
||
Issuance of common stock |
|
|
2,532 |
|
|
|
379 |
|
||
Payments of equity issue costs |
|
|
(181 |
) |
|
|
- |
|
||
NET CASH USED IN FINANCING ACTIVITIES |
|
|
(10,304 |
) |
|
|
(1,454 |
) |
||
|
|
|
|
|
|
|
|
|
||
NET DECREASE IN CASH AND CASH EQUIVALENTS |
|
|
(1,634 |
) |
|
|
(737 |
) |
||
|
|
|
|
|
|
|
|
|
||
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD |
|
|
23,420 |
|
|
|
33,689 |
|
||
CASH AND CASH EQUIVALENTS, END OF PERIOD |
|
$ |
21,786 |
|
|
$ |
32,952 |
|
||
|
|
|
|
|
|
|
|
|
||
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: |
||||||||||
Interest paid |
|
$ |
2,691 |
|
|
$ |
417 |
|
||
Income taxes paid |
|
$ |
222 |
|
|
$ |
20 |
|
||
|
|
|||||||||
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING INFORMATION: |
||||||||||
Equipment acquired under capital lease obligations |
|
$ |
2,585 |
|
|
$ |
3,400 |
|
7
Use of non-GAAP Financial Measures
The Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States of America (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of core operating results across reporting periods. Management also uses non-GAAP financial measures for financial and operational decision making, planning and forecasting purposes and to manage the Company’s business. Management believes that these non-GAAP financial measures enable investors to evaluate our operating results and future prospects in the same manner as management. The non-GAAP financial measures do not replace the presentation of GAAP financial results and should only be used as a supplement to and not as a substitute for the Company’s financial results presented in accordance with GAAP. There are limitations inherent in non-GAAP financial measures because they exclude charges and credits that are required to be included in a GAAP presentation, and do not therefore present the full measure of the Company’s recorded costs against its net revenue. In addition, the Company’s definition of the non-GAAP financial measures below may differ from non-GAAP measures used by other companies.
Definitions of non-GAAP measures
Non – GAAP Adjusted EBITDA
“Adjusted EBITDA” is defined by NeoGenomics as net income from continuing operations before: (i) interest expense, (ii) tax expense, (iii) depreciation and amortization expense, (iv) non-cash, stock-based compensation expense, and if applicable in a reporting period (v) acquisition related transaction expenses and other significant non-recurring or non-operating (income) or expenses.
Non – GAAP Adjusted Net Income
“Adjusted Net Income” is defined by NeoGenomics as net income available to common shareholders from continuing operations plus: (i) non-cash amortization of customer lists and other intangible assets, (ii) non-cash, stock-based compensation expense, (iii) non-cash deemed dividends on preferred stock, (iv) non-cash amortization of preferred stock beneficial conversion feature, and if applicable in a reporting period (v) acquisition related transaction expenses and other significant non-recurring or non-operating (income) or expenses.
Non-GAAP Adjusted EPS
“Adjusted EPS” is defined by NeoGenomics as Adjusted Net Income divided by Adjusted Basic Shares (Adjusted Basic EPS) and Adjusted Diluted Shares outstanding (Adjusted Diluted EPS). Adjusted Basic Shares and Adjusted Diluted Shares include the weighted average number of common shares that would be outstanding if the preferred stock were converted into common stock on the original issue date based on the number of days such common shares would have been outstanding in the reporting period. In addition, If GAAP Net Income is negative and Adjusted Net Income is positive, Adjusted Diluted Shares will also include any options or warrants that would be outstanding as dilutive instruments using the treasury stock method.
Basis for Non-GAAP Adjustments
NeoGenomics basis for excluding certain expenses (income) from GAAP financial measures, are outlined below:
|
· |
Amortization of intangible assets –The intangible assets that give rise to this amortization expense relate to acquisitions, and the amounts allocated to such intangible assets and the terms of amortization vary by acquisition and type of asset. NeoGenomics excludes these items to provide a consistent basis for comparing operating results across reporting periods, pre and post-acquisition. |
8
|
· |
Stock-based compensation expenses – Although stock-based compensation is an important aspect of the compensation paid to NeoGenomics employees, the related expense is substantially driven by changes in the Company’s stock price in any given quarter, which can fluctuate significantly from quarter to quarter and result in large positive or negative impacts to total operating expenses. The variable accounting treatment causing expense to be driven by changes in quarterly stock price is required because many of the company’s full-time Physicians reside in California and are classified as consultants rather than employees due to State regulations. GAAP provides that variable stock based compensation treatment be applied for consultants but not for employees. Without adjusting for these non-cash expenses, the Company believes it would be difficult to compare financial results from core operations across reporting periods on a consistent basis. |
|
· |
Deemed dividends on preferred stock – GAAP accounting for the unique structure of NeoGenomics’ Series A Redeemable Preferred Stock requires the Company to assume that such preferred stock will be outstanding for its entire ten year term. In addition, GAAP requires that the escalating preferred dividend rate over time be accelerated for accounting purposes and amortized on a straight-line basis over the ten-year life of the instrument, irrespective of the minimal contractual requirements for “paid in kind” stock dividends in the early years. Since such implied dividends are not paid in cash, and since the Company believes that such preferred stock will be redeemed within the first three years it is outstanding, before any significant dividends have accrued under the contractual terms, the Company believes these non-cash expenses are not meaningful in evaluating the operating performance of the Company and it would be misleading to not adjust for such expenses across reporting periods. |
|
· |
Amortization of preferred stock beneficial conversion feature – This significant non-cash expense is also a direct result of the complex GAAP accounting requirements for our Series A Redeemable Preferred Stock. The Company believes this expense is not meaningful in evaluating the operating performance of the Company, distorts comparisons across reporting periods, and that it would be misleading to not adjust for such expenses across reporting periods. |
NeoGenomics, Inc.
Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Adjusted EBITDA
(Unaudited, in thousands)
|
|
For the Three Months Ended June 30, |
|
|
For the Six Months Ended June 30, |
|
||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
Net Income (Loss) (per GAAP) |
|
$ |
413 |
|
|
$ |
(176 |
) |
|
$ |
568 |
|
|
$ |
(937 |
) |
Adjustments to Net Income (Loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
1,448 |
|
|
|
189 |
|
|
|
3,040 |
|
|
|
384 |
|
Income tax expense |
|
|
332 |
|
|
|
15 |
|
|
|
505 |
|
|
|
19 |
|
Amortization of intangibles |
|
|
1,610 |
|
|
|
97 |
|
|
|
3,636 |
|
|
|
190 |
|
Depreciation |
|
|
3,744 |
|
|
|
1,663 |
|
|
|
7,329 |
|
|
|
3,249 |
|
EBITDA |
|
|
7,547 |
|
|
|
1,788 |
|
|
|
15,078 |
|
|
|
2,905 |
|
Further Adjustments to EBITDA: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash stock based compensation |
|
|
1,634 |
|
|
|
619 |
|
|
|
2,337 |
|
|
|
1,020 |
|
Adjusted EBITDA (non-GAAP) |
|
$ |
9,181 |
|
|
$ |
2,407 |
|
|
$ |
17,415 |
|
|
$ |
3,925 |
|
9
NeoGenomics, Inc.
Reconciliation of GAAP Net Income Available to Common Stockholders to Non-GAAP Adjusted Net Income and GAAP Earnings per Share to Non-GAAP Adjusted Earnings per Share
(Unaudited, in thousands)
|
|
For the Three Months Ended June 30, |
|
|
For the Six Months Ended June 30, |
|
|||||||||||||||||||||
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
|||||||||||||||
Net income (loss) available to common stockholders (GAAP) |
|
$ |
(5,154) |
|
$ |
|
(176) |
|
|
$ |
(10,565) |
|
|
$ |
(937) |
|
|||||||||||
Adjustments to Net Loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Amortization of intangibles |
|
|
1,610 |
|
|
|
97 |
|
|
|
3,636 |
|
|
|
190 |
|
|||||||||||
Deemed dividends on preferred stock |
|
|
1,840 |
|
|
|
— |
|
|
|
3,680 |
|
|
|
— |
|
|||||||||||
Amortization of preferred stock beneficial conversion feature |
|
|
3,727 |
|
|
|
— |
|
|
|
7,453 |
|
|
|
— |
|
|||||||||||
Non-cash stock based compensation expenses |
|
|
1,634 |
|
|
|
619 |
|
|
|
2,337 |
|
|
|
1,020 |
|
|||||||||||
Adjusted net income (non-GAAP) |
|
$ |
3,657 |
|
|
$ |
540 |
|
|
$ |
6,541 |
|
|
$ |
273 |
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Net loss per common share (GAAP) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Basic EPS |
|
$ |
(0.07) |
|
|
$ |
(0.00) |
|
|
$ |
(0.14) |
|
|
$ |
(0.02) |
|
|||||||||||
Diluted EPS |
|
$ |
(0.07) |
|
|
$ |
(0.00) |
|
|
$ |
(0.14) |
|
|
$ |
(0.02) |
|
|||||||||||
Adjustments to Loss per Share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Amortization of intangibles |
|
$ |
0.02 |
|
|
$ |
0.00 |
|
|
$ |
0.05 |
|
|
$ |
0.00 |
|
|||||||||||
Non-cash stock based compensation expenses |
|
$ |
0.03 |
|
|
$ |
0.01 |
|
|
$ |
0.03 |
|
|
$ |
0.02 |
|
|||||||||||
Deemed dividends on preferred stock |
|
$ |
0.02 |
|
|
|
— |
|
|
$ |
0.05 |
|
|
|
— |
|
|||||||||||
Amortization of preferred stock beneficial conversion feature |
|
$ |
0.05 |
|
|
$ |
— |
|
|
$ |
0.10 |
|
|
$ |
— |
|
|||||||||||
Adjusted net income per common share (non-GAAP): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Adjusted Basic |
|
$ |
0.04 |
|
|
$ |
0.01 |
|
|
$ |
0.07 |
|
|
$ |
0.00 |
|
|||||||||||
Adjusted Diluted |
|
$ |
0.04 |
|
|
$ |
0.01 |
|
|
$ |
0.07 |
|
|
$ |
0.00 |
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Weighted average shares used in computation of adjusted earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
GAAP Basic Common Shares outstanding |
|
|
77,448 |
|
|
|
60,425 |
|
|
|
76,758 |
|
|
|
60,352 |
|
|||||||||||
Weighted Avg. Preferred Shares (as converted) |
|
|
14,667 |
|
|
|
— |
|
|
|
14,667 |
|
|
|
— |
|
|||||||||||
Adjusted Basic Shares outstanding |
|
|
92,115 |
|
|
|
60,425 |
|
|
|
91,425 |
|
|
|
60,352 |
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Diluted Common Shares (GAAP) |
|
|
77,448 |
|
|
|
60,425 |
|
|
|
76,758 |
|
|
|
60,352 |
|
|||||||||||
Options and warrants not included in GAAP Diluted Shares (using treasury stock method) |
|
|
2,297 |
|
|
|
2,826 |
|
|
|
1,951 |
|
|
|
2,609 |
|
|||||||||||
Weighted Avg. Preferred Shares (as converted) |
|
|
14,667 |
|
|
|
— |
|
|
|
14,667 |
|
|
|
— |
|
|||||||||||
Adjusted Diluted Shares outstanding (non-GAAP) |
|
|
94,412 |
|
|
|
63,251 |
|
|
|
93,376 |
|
|
|
62,961 |
|
10
Supplemental Information on
Clinical Genetic(1) Requisitions Received, Tests Performed, Revenue and Cost of Revenue
(unaudited, in thousands, except test & requisition data and per test & per requisition data)
|
For the Three-Months Ended June 30, |
For the Six-Months Ended June 30, |
||||||||||
|
||||||||||||
Consolidated |
|
2016 |
|
2015 |
% Change |
|
|
2016 |
|
2015 |
% Change |
|
Requisitions received (cases) |
|
90,795 |
|
34,147 |
165.9% |
|
|
179,619 |
|
65,244 |
175.3% |
|
Number of tests performed |
|
140,822 |
|
54,632 |
157.8% |
|
|
275,726 |
|
103,748 |
165.8% |
|
Average number of tests/requisition |
|
1.55 |
|
1.60 |
(3.1%) |
|
|
1.54 |
|
1.59 |
(3.5%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total clinical genetic testing revenue |
$ |
54,249 |
$ |
22,118 |
145.3% |
|
$ |
106,999 |
$ |
42,615 |
151.1% |
|
Average revenue/requisition |
$ |
597 |
$ |
648 |
(7.8%) |
|
$ |
596 |
$ |
653 |
(8.8%) |
|
Average revenue/test |
$ |
385 |
$ |
405 |
(4.9%) |
|
$ |
388 |
$ |
411 |
(5.5%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue |
$ |
29,153 |
$ |
11,832 |
146.4% |
|
$ |
56,921 |
$ |
23,415 |
143.1% |
|
Average cost/requisition |
$ |
321 |
$ |
346 |
(7.3%) |
|
$ |
317 |
$ |
359 |
(11.7%) |
|
Average cost/test |
$ |
207 |
$ |
217 |
(4.4%) |
|
$ |
206 |
$ |
226 |
(8.5%) |
Supplemental Information on
PathLogic Requisitions Received, Tests Performed, Revenue and Cost of Revenue
(unaudited, in thousands, except requisition data and revenue & cost per requisition)
|
For the Three-Months Ended June 30, |
For the Six-Months Ended June 30, |
||||||||||
|
||||||||||||
PathLogic |
|
2016 |
|
2015 |
% Change |
|
|
2016 |
|
2015 |
% Change |
|
Requisitions received (cases) |
|
14,177 |
|
17,039 |
(16.8%) |
|
|
27,833 |
|
33,700 |
(17.4%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total testing revenue |
$ |
2,066 |
$ |
1,937 |
6.6% |
|
$ |
3,937 |
$ |
4,280 |
(8.0%) |
|
Average revenue/requisition |
$ |
146 |
$ |
114 |
28.2% |
|
$ |
141 |
$ |
127 |
11.4% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue |
$ |
1,941 |
$ |
1,673 |
16.0% |
|
$ |
3,618 |
$ |
3,500 |
3.4% |
|
Average cost/requisition |
$ |
137 |
$ |
98 |
39.5% |
|
$ |
130 |
$ |
104 |
25.2% |
11
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end